India prostate cancer diagnostic and therapeutic market was valued at $1,242.0 million in 2025 and is projected to reach $2,990.4 million by 2035, growing at a CAGR of 9.2% during the forecast period (2026-2035). India’s increasing prostate cancer burden and the demographic shift toward an older male population constitute a primary driver for market sizing and revenue projections. National Cancer Registry Programme projections indicate a continued rise in prostate cancer incidence in India, with new cases estimated to increase from approximately 41,532 in 2020 to around 47,068 by 2025. This upward trajectory reflects the expanding disease burden driven by demographic ageing and improved detection rates. The projected growth in annual diagnoses directly strengthens demand for prostate-specific antigen testing, biopsy procedures, advanced imaging modalities, and systemic therapeutic interventions. From a market estimation standpoint, the 2025 incidence level provides a stronger volume base for forecasting diagnostic utilization and treatment adoption across public and private healthcare facilities.
Browse the full report description of “India Prostate Cancer Diagnosis & Treatment Market Size, Share & Trends Analysis Report by Diagnostic Technique (Prostate Specific Antigen Test, Digital Rectal Exam), by Therapy (Hormonal Therapy, Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy) Forecast Period, 2026–2035” at https://www.omrglobal.com/industry-reports/indian-prostate-cancer-diagnostic-therapeutic-market
Prostate cancer in India is predominantly diagnosed in men aged 65 years and above, a demographic that often presents with coexisting chronic conditions. This age concentration increases clinical complexity and influences treatment decision-making, encouraging the adoption of minimally invasive diagnostics, precision imaging, and therapies with improved safety profiles. Physicians increasingly prefer options that reduce hospitalization time and limit adverse effects, particularly in elderly patients managing multiple medications.
Innovation Leaders Transforming the India Prostate Cancer Diagnostic and Therapeutic Market
The key players in the India prostate cancer diagnostic and therapeutic market include Astellas Pharma Inc., Pfizer Inc., Johnson & Johnson (Janssen), Novartis AG, AstraZeneca plc, among others. These companies are driving innovation in the prostate cancer market through the development of next-generation immunotherapies, PSMA-targeted radiopharmaceuticals, precision imaging agents, and advanced molecular diagnostic platforms. Their focus on improving treatment efficacy, enhancing safety profiles, enabling earlier and more accurate detection, and supporting personalized therapy approaches is accelerating progress in advanced and metastatic prostate cancer care across global healthcare markets.
Market Coverage
Key questions addressed by the report.
India Prostate Cancer Diagnostic and Therapeutic Market Report Segment
By Diagnostic Technique
By Therapeutics
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/indian-prostate-cancer-diagnostic-therapeutic-market